Mark A. Kay
FounderDr. Mark A. Kay, Ph.D., M.D., served as Member of Gene Therapy Scientific Advisory Board of Poseida Therapeutics, Inc. since March 2023. He serves as Member of Scientific Advisory Board at SonoThera, Inc. from December 2024. He serves as a Scientific Advisor at Carmine Therapeutics Inc. He has been Member of Scientific Advisory Board at Apic Bio, Inc. since July 2020. He has been Scientific Advisor & Member of Scientific Advisory Board at Carmine Therapeutics Pte Ltd. He has been Member of Scientific Advisory Board at Kriya Therapeutics, Inc. Dr. Kay served as Chairman of Scientific Advisory Board at LogicBio Therapeutics, Inc. until November 16, 2022. He served as an Independent Director at LogicBio Therapeutics, Inc., since January 2016 until November 16, 2022. Dr. Kay is a Member of Scientific Advisory Board of Tenaya Therapeutics, Inc. He is Co-Founder of LogicBio Therapeutics, Inc. and served as Director of the Program in Human Gene Therapy/Head of Division of Human Gene Therapy, Departments of Pediatrics and Genetics at Stanford University School of Medicine. As a Pioneer in the field of human gene therapy, Dr. Kay has tremendous expertise. He is the Founder of Voyager Therapeutics, Inc. Dr. Kay served as Member of Scientific Advisory Board of OliX Pharmaceuticals, Inc. until April 2019. He is an Editor of Human Gene Therapy. He co-founded the American Society of Gene and Cell Therapy and was its President from 2005 to 2006 and Vice President. He served as the President of American Society from 2005 to 2006. He Co-Founded Avocel, Inc. and served as its Chairman of Scientific Advisory Board. He had been Member of Scientific Advisory Board at Applied StemCell Inc.since December 19, 2017. He had been a Member of Scientific Advisory Board at Sigilon Therapeutics, Inc. since October 09, 2017 until 2019. He served as a Member of Strategic Advisory Board and Member of Scientific and Medical Advisory Board at Medgenics, Inc. (now Aevi Genomic Medicine, Inc.). He served as a Member of Scientific Advisory Board at Intradigm Corporation and Silence Therapeutics Plc. He is a Professor in the Departments of Pediatrics and Genetics at Stanford University School of Medicine. He is Associate Chair of Research in Pediatrics at Stanford University. He served at the University of Washington as Associate Professor in the Departments of Medicine, with adjuncts in Pediatrics, Biochemistry and Pathology. He serves on the editorial boards of other peer-reviewed publications. He serves on the Board of the Oligonucleotide Therapeutics Society and is founding Member of the American Society for Gene Therapy. He was elected to the American Society for Clinical Investigation in 1997 and the Association for American Physicians in 2010. He has organized many national and international conferences, including the first Gordon Conference related to gene therapy. Dr. Kay was honored as 2013 Researcher of the Year by the National Hemophilia Foundation and is the recipient of the American Society for Gene and Cell Therapy 2013 Outstanding Investigator Award. He received the E. Mead Johnson Award for Research in Pediatrics in 2000. He is respected worldwide for his work in vector development, gene therapy for hemophilia and viral hepatitis and non-coding RNA biology. He is a leading Researcher in the fields of gene therapy and AAV biology, including the identification of new AAV capsids. He is an avid and skilled Photographer with an extensive portfolio of nature photographs including the avocet photos used on this site. Dr. Kay holds a BS in Physical Sciences from Michigan State University and a Ph.D. in Developmental Genetics and M.D. from Case Western Reserve University.
Positions
- Company NameVoyager Therapeutics, Inc.Stock CodeVYGRPositionFounderColleagues
